On Wednesday, March 25, historic legislation to make insulin more affordable was introduced in the US Senate. Senators Jeanne Shaheen (D-NH), Susan Collins (R-ME), Raphael Warnock (D-GA), and John Kennedy (R-LA) introduced the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2026. The INSULIN Act would expand the $35 monthly cap on out-of-pocket insulin costs, currently available for Medicare beneficiaries, to those with private insurance. The legislation also would create a program to provide lower cost insulin to the uninsured. The Endocrine Society has endorsed this bipartisan legislation, and we need your help asking your Senators to cosponsor and advance the INSULIN Act in the Senate HELP Committee. It is imperative that your senators hear from you about the importance of cosponsoring this legislation and supporting this bill. We urge all Endocrine Society members to take action today and ask your Senators to cosponsor and pass this legislation quickly. You can take action today by clicking here.
Funding for the National Institutes of Health (NIH) is in danger. The President has proposed significant cuts to NIH and FY 2026 funds have been held up or unilaterally withdrawn, and delays and disruptions to grant reviews persist. The Endocrine Society is urging Congress to protect the NIH and provide the NIH with at least $51.303 billion in FY 2027. It is imperative that all Senators and Representatives hear from their constituents about the importance of NIH funding. Take action and join our campaign today.
The Endocrine Society’s next scientific statement - Obesity Science, Research Gaps and Opportunities in the New Era of Obesity Medicines: An Endocrine Society Scientific Statement is available for member comment. Developed by a writing group led by Daniel J. Drucker, MD, and Ania M. Jastreboff, MD, PhD, the statement has already undergone several stages of a rigorous review process. Internal reviews have been conducted by the Scientific Statement Subcommittee, the Research Affairs Core Committee, and expert external reviewers prior to the member comment period. To protect the Society's copyright and prevent multiple drafts from being circulated, please do not circulate this draft statement. Currently, we are seeking comments from Society members only. Your comments will be reviewed by the authors and will be considered in the preparation of the final document. This comment period will be deactivated at 5:00 PM ET on Wednesday, April 15. Thank you in advance for taking the time to review and comment on this Statement. Please feel free to contact Joe Laakso at [email protected] if you have any questions.
We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your US representatives or European Members of Parliament through our online platform. Take action and make a difference today.
